Moscow, Russia - October 22nd, 2016. Institute for Systems Biology Moscow (www.insysbio.ru), a private research organization focused on application of quantitative system pharmacology (QSP) modeling to different stages of drug research and development, today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016.
Oleg Demin Jr, Senior Modeler at Institute for Systems Biology Moscow will present two posters on application of QSP modelling in HCV therapeutic area.
Poster entitled "Prediction of Treatment Efficacy of Direct Antiviral Agent Combinations in Chronic Hepatitis C Patients Using Quantitative Systems Pharmacology Modeling Approach" on Monday, October 24th, 2016 at 7:30am to 9:30am. The poster will demonstrate predictions of results of ongoing clinical trials of direct antiviral agents combinations for chronic hepatitis C patients with genotype 1. QSP model predicts primary endpoint SVR12 quantifying percent of patients with undetectable hepatitis C virus during 12 weeks after treatment completion. Poster ID is M45.
Poster entitled “Modeling of immune response suppression by hepatitis C virus and nivolumab treatement in chronic hepatitis C patients using quantitative systems pharmacology approach" on Tuesday, October 25th, 2016 at 7:30am to 9:00am. The poster will demonstrate how QSP model can describe suppression of immune response by hepatitis C virus. The model was applied to predict and explore results of treatment of chronic hepatits C patients with PD-1 inhibitor nivolumab. Poster ID is T56.
Institute for Systems Biology Moscow, Ltd. (www.insysbio.ru) is a leading R&D company providing services for mathematical modeling in drug research and development. ISBM is one of the pioneers in quantitative system pharmacology (QSP) modeling and simulation services and has been working on the market for more than 10 years. The company’s aim is to assist right decisions on the critical stages of drug research and development. ISBM team continuously improves methods and tools for biological modeling. Moreover, company works with students and postgraduates forming professional community of QSP-modelers. Company has published a lot of scientific studies, and has presented at major international conferences of the field. The ISBM innovative approach has become an integral part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharma industry.
Media contact:
Maria Maximova, media@insysbio.ru
| ← | March 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Mar 2020 12:25
13th InSysBio Annual Internal Scientific Meeting
26-28 February 2020 InSysBio QSP-company held its 13th Annual Internal Scientific Meeting. InSysBio team presented the results of 2019 year professional progress. Every member demonstrated their personal achievements and shared the plans for the future development. Oleg Demin, InSysBio CEO and founder, summarized all the company’s advancement of the year 2019.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
1.
10 Mar 2020 12:48
InSysBio to share the news from QSPC2020 management
Today we have received the concerning news from QSPC2020 organizers about the cancellation of the conference in response to COVID-19 outbreak continuation. Quantitative Systems Pharmacology Conference 2020 was planned to be held in April 22-24, 2020 Leiden, The Netherlands. InSysBio team was prepared to present 10 posters
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
